HUYABIO International
Akira Miyazato is the Site Head and Vice President of Clinical Development Japan at HUYA Bioscience International. Miyazato is also the CEO of EMHCS INC, with a background in Health Care, Medicine, Nursing Care, Pharmaceuticals, and ICT Innovation. Miyazato previously held positions at グラクソスミスクライン株式会社 as a Vice Center Manager and Department Manager in rare disease pharmaceutical development and antibody/oncology drug development respectively. Miyazato holds a Doctor of Medicine degree in molecular biology and bioinformatics from Jichi Medical University and a Bachelor of Medicine degree from the University of the Ryukyus.
This person is not in any offices
HUYABIO International
HUYABIO is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland and eight strategic locations across China, the Company has become a partner of choice to accelerate product development and maximize value globally.